Mepolizumab response in severe chronic rhinosinusitis with nasal polyps is dissociated from blood eosinophil levels

Affiliations

¹ Scottish Centre for Respiratory Research and Rhinology Mega-clinic, Ninewells Hospital and Medical School, Dundee, United Kingdom. Electronic address: b.j.lipworth@dundee.ac.uk.
² Scottish Centre for Respiratory Research and Rhinology Mega-clinic, Ninewells Hospital and Medical School, Dundee, United Kingdom.

Comment

Brian Lipworth et al. J Allergy Clin Immunol. 2022 May.

. 2022 May;149(5):1817.

doi: 10.1016/j.jaci.2022.02.017. Epub 2022 Mar 10.

¹ Scottish Centre for Respiratory Research and Rhinology Mega-clinic, Ninewells Hospital and Medical School, Dundee, United Kingdom. Electronic address: b.j.lipworth@dundee.ac.uk.
² Scottish Centre for Respiratory Research and Rhinology Mega-clinic, Ninewells Hospital and Medical School, Dundee, United Kingdom.

No abstract available

Comment on

Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count.
Bachert C, Sousa AR, Han JK, Schlosser RJ, Sowerby LJ, Hopkins C, Maspero JF, Smith SG, Kante O, Karidi-Andrioti DE, Mayer B, Chan RH, Yancey SW, Chaker AM. Bachert C, et al. J Allergy Clin Immunol. 2022 May;149(5):1711-1721.e6. doi: 10.1016/j.jaci.2021.10.040. Epub 2022 Jan 7. J Allergy Clin Immunol. 2022. PMID: 35007624 Clinical Trial.